This is what MM are saying today
A former top Food and Drug Administration (FDA) official believes it’s most likely that marijuana will be put in Schedule III of the Controlled Substances Act (CSA) following an ongoing administrative review ordered by President Biden last year. FDA is mindful of political factors such as the 2024 election, the official said, so a policy change may come sooner rather than later.
Howard Sklamberg, who previously served as chair of FDA’s Marijuana Working Group from 2014 to 2017, spoke about the possible outcomes of the review, the impact of rescheduling and the agency’s timeline on a Mindset Capital podcast released on Thursday.
There are two things that “certainly won’t happen” with FDA’s scheduling review, Sklamberg predicted: a recommendation to keep cannabis in Schedule I or guidance to deschedule it altogether.
The agency has more flexibility since it last looked into marijuana scheduling, in 2016, so maintaining the status quo is unlikely, he said. On the other hand, descheduling “would be extremely difficult for FDA” given regulatory restraints.
Read More at
Per FDA website this is how they define schedule III
Schedule III
Schedule III drugs, substances, or chemicals are defined as drugs with a moderate to low potential for physical and psychological dependence. Schedule III drugs abuse potential is less than Schedule I and Schedule II drugs but more than Schedule IV. Some examples of Schedule III drugs are: products containing less than 90 milligrams of codeine per dosage unit (Tylenol with codeine), ketamine, anabolic steroids, testosterone
